Malaria Policy Advisory Committee
The Malaria Policy Advisory Committee (MPAC) was established in 2011 to provide independent advice to WHO on developing policy recommendations to control and eliminate malaria. An independent advisory group bringing together the world’s foremost experts on malaria, the MPAC provides strategic technical guidance to WHO as part of a transparent, responsive and credible policy-setting process on malaria.
The MPAC advises the WHO Director-General specifically on:
- appropriate malaria policies and standards based on data from malaria programme implementation by Member States and malaria control partners as well as reviews of the best available evidence;
- engagement of WHO in malaria-related initiatives;
- major issues and challenges to achieving global malaria goals; and
- the identification of priority activities to address identified challenges.
The scale-up of malaria control efforts in recent years, coupled with major investments in malaria research, has produced impressive public health impact in a number of countries, and has led to the development of new tools and strategies aimed at further consolidating malaria control goals. As a result, there was a growing need for WHO to rapidly review increasing amounts of evidence and update technical recommendations.
The MPAC was set up following an extensive review of the policy-setting process for malaria control and elimination, initiated by the WHO Global Malaria Programme. The process was conducted with the help of a specially convened external Advisory Group who reviewed previous and existing WHO/GMP policy processes and successful policy models from other WHO departments. It was this group that proposed the concept and architecture of a permanent strategic advisory committee. The MPAC’s inaugural meeting was held in January 2012.
MPAC recommendations and conclusions are published on this website, and a detailed report of each meeting is published in the Malaria Journal.
Technical Expert Groups and Evidence Review Groups
Under the auspices of the MPAC, three standing Technical Expert Groups (TEGs) have been established: on Chemotherapy, on Drug Resistance and Containment, and on Vector Control. In addition, three time-limited and specific Evidence Review Groups (ERGs) have been set up to review and provide evidence-based information and options for recommendations. Recommendations emerging from the TEGs and ERGs are discussed by the full MPAC in open sessions.